After adjusting for age, sex, BMI, Ann Arbor stage, ECOG PS, CD4+T cell shift, and Hb shift, the association remained significant (OR = 9.18; 95% CI: 2.73–30.86; p < 0.01), indicating that Alb Change Rate may serve as an independent predictor of therapeutic response in AR-NHL. Here, CD4 is linked to non-Hodgkin lymphoma.